Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

13.31

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.09

EPS Last/This Y

0.57

EPS This/Next Y

0.39

Price

5

Target Price

17.22

Analyst Recom

1.2

Performance Q

-4.21

Relative Volume

0.67

Beta

1.25

Ticker: VIR




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15VIR4.510.250.028944
2025-08-18VIR4.470.220.008003
2025-08-19VIR4.360.220.008030
2025-08-20VIR4.360.220.138063
2025-08-21VIR4.380.220.008077
2025-08-22VIR4.580.220.008134
2025-08-25VIR4.380.220.048134
2025-08-26VIR4.450.220.008158
2025-08-27VIR5.230.210.068248
2025-08-28VIR5.030.200.089161
2025-08-29VIR4.950.200.219181
2025-09-02VIR50.200.019252
2025-09-03VIR5.520.200.819279
2025-09-04VIR5.140.210.049543
2025-09-05VIR5.280.200.159744
2025-09-08VIR5.20.200.139742
2025-09-09VIR5.240.200.1410012
2025-09-10VIR5.130.200.6510274
2025-09-11VIR5.240.200.0010293
2025-09-12VIR5.010.190.3510470
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15VIR4.5242.1- -3.26
2025-08-18VIR4.4744.8- -3.26
2025-08-19VIR4.3644.8- -3.26
2025-08-20VIR4.3544.8- -3.26
2025-08-21VIR4.3844.8- -3.26
2025-08-22VIR4.5744.8- -3.26
2025-08-25VIR4.3744.8- -3.26
2025-08-26VIR4.4444.8- -3.26
2025-08-27VIR5.2244.8- -3.26
2025-08-28VIR5.0444.8- -3.26
2025-08-29VIR4.9544.8- -3.26
2025-09-02VIR5.0044.8- -3.26
2025-09-03VIR5.5244.8- -3.26
2025-09-04VIR5.1444.8- -3.26
2025-09-05VIR5.2744.8- -3.26
2025-09-08VIR5.1944.8- -3.26
2025-09-09VIR5.2444.8- -3.26
2025-09-10VIR5.1344.8- -3.26
2025-09-11VIR5.2344.8- -3.26
2025-09-12VIR5.0044.8- -3.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15VIR-0.417.2412.43
2025-08-18VIR-0.419.3812.44
2025-08-19VIR-0.419.3812.44
2025-08-20VIR-0.399.3812.44
2025-08-21VIR-0.399.3812.44
2025-08-22VIR-0.399.3812.44
2025-08-25VIR-0.396.3712.44
2025-08-26VIR-0.296.3712.44
2025-08-27VIR-0.296.3712.83
2025-08-28VIR-0.286.3712.83
2025-08-29VIR-0.286.3712.83
2025-09-02VIR-0.286.1312.83
2025-09-03VIR-0.326.1312.83
2025-09-04VIR-0.326.1312.83
2025-09-05VIR-0.326.1312.83
2025-09-08VIR-0.326.1412.82
2025-09-09VIR-0.326.1412.82
2025-09-10VIR-0.326.1412.82
2025-09-11VIR-0.326.1413.31
2025-09-12VIR-0.326.1413.31
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.8

Avg. EPS Est. Current Quarter

-0.86

Avg. EPS Est. Next Quarter

-0.71

Insider Transactions

-0.32

Institutional Transactions

6.14

Beta

1.25

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

32

Growth Score

31

Sentiment Score

35

Actual DrawDown %

96.5

Max Drawdown 5-Year %

-94.8

Target Price

17.22

P/E

Forward P/E

PEG

P/S

36.56

P/B

0.73

P/Free Cash Flow

EPS

-4.01

Average EPS Est. Cur. Y​

-3.26

EPS Next Y. (Est.)

-2.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2895.94

Relative Volume

0.67

Return on Equity vs Sector %

-82.9

Return on Equity vs Industry %

-69.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.16

EBIT Estimation

Vir Biotechnology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 408
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
stock quote shares VIR – Vir Biotechnology, Inc. Stock Price stock today
news today VIR – Vir Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VIR – Vir Biotechnology, Inc. yahoo finance google finance
stock history VIR – Vir Biotechnology, Inc. invest stock market
stock prices VIR premarket after hours
ticker VIR fair value insiders trading